Claims
- 1. A composition for inhibiting the side-effects of retinoids topically applied to human skin or administered systemically to a patient in need thereof, comprising an admixture of a natural inhibitor of EGFR activation or a derivative or analog thereof and a dermatologically suitable carrier therefor.
- 2. The composition of claim 1, wherein the inhibitor is a reversible inhibitor.
- 3. The compostion of claim 1, wherein the inhibitor is an irreversible inhibitor.
- 4. The composition of claim 1, comprising a mixture of a reversible inhibitor and an irreversible inhibitor.
- 5. The composition of claim 1, wherein the inhibitor is an isoflavone.
- 6. The composition of claim 1, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 7. The composition of claim 6, wherein the inhibitor is genistein and is derived from a soy product.
- 8. A composition for treating a dermatological condition in human skin, comprising in admixture: a retinoid, a natural inhibitor of EGFR activation compatible with said retinoid, and a dermatologically carrier for said admixture.
- 9. The composition of claim 8, wherein the retinoid is selected from the group consisting of vitamin A (retinol), vitamin A aldehyde (retinal), vitamin A acid (retinoic acid, including all-trans, 9-cis, and 13-cis retinoic acid), adapalene, tazarotene, and mixtures thereof.
- 10. The composition of claim 8, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 11. A method of treatment, comprising use of a natural inhibitor of EGFR in combination with the administration of a retinoid, whether topically, orally, or both to a human patient having a skin condition responsive to the administration of said retinoid.
- 12. The method of claim 11, wherein the retinoid is administered topically between four times daily and once weekly.
- 13. The method of claim 11, wherein the retinoid is selected from the group consisting of vitamin A (retinol), vitamin A aldehyde (retinal), vitamin A acid (retinoic acid, including all-trans, 9-cis, and 13-cis retinoic acid), etretinate, acetretin, adapalene, tazarotine, and mixtures thereof.
- 14. The method of claim 11, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 15. During a treatment of a patient comprising the use of a compound and/or energy administered to said patient, which compound or energy administered happens to activate/phosphorylate the epidermal growth factor receptor (EGFR), the improvement comprising use a natural inhibitor of EGFR activation/phosphorylation during use of such compound.
- 16. The improved method of claim 15, wherein the energy includes irradiating with UV radiation.
- 17. The improved method of claim 15, wherein the compound is a retinoid.
- 18. The improved method of claim 15, wherein the retinoid is used topically.
- 19. The improved method of claim 15, wherein the retinoid is used orally.
- 20. The improved method of claim 15, wherein the inhibitor is an isoflavone.
- 21. The improved method of claim 20, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 22. The improved method of claim 21, wherein the genistein is derived from a soy product.
- 23. The improved method of claim 15, wherein the inhibitor is used prior to the start of the treatment regimen using said compound and/or energy.
- 24. The improved method of claim 15, wherein the inhibitor is used after the treatment regimen with said compound and/or energy has ended.
- 25. A cleansing composition for a human or other animal, comprising:
A. a cleanser selected from the goup consisting of soaps, surfactants, detergents, and mixtures thereof; and B. an effective amount of a natural EGFR inhibitor.
- 26. The cleanser of claim 25, wherein the EGFR inhibitor is present in an amount between 0.1% and 10% by weight.
- 27. The cleanser of claim 26, wherein the EGFR inhibitor is present in an amount between 1% and 7% by weight.
- 28. The cleanser of claim 25, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole, staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 29. The cleanser of claim 28, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, and mixtures thereof.
- 30. The cleanser of claim 28, wherein the inhibitor is provided as a ground or powdered soy (soya) product, including soy bean.
- 31. The cleanser of claim 25, wherein the cleanser is a cleanser for use on animals.
- 32. A composition for alleviating peeling due to hyperproliferation of skin cells, comprising a natural inhibitor of EGFR and a dermatologically suitable carrier therefor.
- 33. The composition of claim 32, wherein the inhibitor is an isoflavone.
- 34. The composition of claim 32, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 35. The composition of claim 32, wherein the inhibitor is genistein and is derived from a soy product.
- 36. A method for preventing peeling due to hyperproliferation of the skin, comprising providing a dermatologically suitable composition of a natural EGFR inhibitor and a suitable carrier therefor, and the topical application of said composition to the affected area of the skin.
- 37. The method of claim 36, wherein the hyperproliferation is due to the administration of a retinoid, and the inhibitor is used prior to said administration, during said administration, and/or after said administration of a retinoid.
- 38. The method of claim 36, wherein the inhibitor is an isoflavone.
- 39. The method of claim 36, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
PRIOR APPLICATIONS
[0001] This application is based on prior provisional application serial number 60/271,894, filed Feb. 27, 2001, the disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60271894 |
Feb 2001 |
US |